文献速递痛风与晶体性关节病

痛风、高尿酸血症与晶体相关疾病网络(G-CAN)对痛风临床缓解的定义

The Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) definition of clinical remission in gout.
PubMed 文献 · Ann Rheum Dis · 2025-06-18

G-CAN在2016年初步定义基础上,经定性研究简化出包含12个月内无痛风发作、无皮下痛风石及血清尿酸<0.36 mmol/L(6 mg/dL)持续12个月的简化定义,并在多项痛风临床试验数据集中评估其效度,最终经G-CAN成员投票(98%支持)和董事会认可,推荐用于评估痛风临床缓解。

要点

  • G-CAN简化定义:12个月内无痛风发作、无皮下痛风石、血清尿酸<0.36 mmol/L(6 mg/dL)持续12个月。
  • 该定义在多项痛风临床试验数据集中显示表面效度、结构效度、预测效度、可行性、反应性和区分度。
  • G-CAN成员投票98%支持,董事会认可,推荐用于评估痛风临床缓解。

核心结论

  • G-CAN定义可行且具有高效度,推荐在评估痛风临床缓解时使用该定义。

研究设计与样本

  • 多阶段项目:在建立简化定义后,依次进行跨痛风临床试验数据集和人群的分析、向G-CAN成员汇报评估与验证结果、G-CAN成员讨论、投票及G-CAN董事会认可。

主要发现

  • 简化定义在多项痛风临床试验数据集中表现出表面效度、结构效度、预测效度、可行性、反应性和区分度。
  • 该定义同时捕获痛风炎症疾病活动和尿酸负荷,并反映患者对痛风缓解的看法。
  • G-CAN成员建议考虑将该定义称为「临床痛风缓解」,因无评估完全晶体溶解的维度。
  • 投票中该定义获98%的G-CAN成员支持,G-CAN董事会认可该定义。

关键数值与推荐

  • 简化定义由三项组成:12个月内无痛风发作、无皮下痛风石、血清尿酸<0.36 mmol/L(6 mg/dL)持续12个月。
  • G-CAN成员投票支持率为98%。

临床怎么用

  • 作者推荐在评估痛风临床缓解时使用该G-CAN定义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In 2016, rheumatologists and gout researchers developed a preliminary definition for gout remission. A subsequent qualitative study involving people with gout identified redundancies in the preliminary definition, prompting the development of a simplified definition consisting of no gout flares over 12 months, absence of subcutaneous tophi and serum urate <0.36 mmol/L (6 mg/dL) over 12 months. Here, we describe the evaluation and validation of the simplified definition and endorsement of this definition as the Gout, Hyperuricemia, and Crystal-Associated Disease Network (G-CAN) definition of clinical remission in gout. METHODS: After establishment of the simplified definition, this multiphase project involved consecutive steps: analysis of the definition across a range of gout clinical trial datasets and study populations, summary of evaluation and validation of this definition presented to G-CAN members, discussion of this definition by G-CAN members, voting and G-CAN Board endorsement. RESULTS: The simplified definition exhibited face validity, construct validity, predictive validity, feasibility, responsiveness, and discrimination across a range of gout clinical trial datasets. It also captured both inflammatory disease activity and urate burden in gout and reflected the patient perspective on gout remission. It was suggested by G-CAN members to consider the definition as one for 'clinical gout remission' since there is no domain evaluating complete crystal dissolution. In voting, this definition was supported by 98% of G-CAN members, and the G-CAN Board endorsed the definition. CONCLUSIONS: The G-CAN definition is feasible and has high validity. We recommend that this definition is used when assessing clinical remission in gout.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Tabi-Amponsah AD, Stewart S, Stamp LK, et al. The Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) definition of clinical remission in gout. Ann Rheum Dis. 2025. PMID: 40537342. doi:10.1016/j.ard.2025.05.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。